Sponsor:
Verastem, Inc.
Code:
NCT05669482
Conditions
KRAS Activating Mutation
Metastatic Cancer
Pancreas Cancer
Neoplasms Pancreatic
Malignant Neoplasm of Pancreas
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations